YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Company Logo Opportunities center on frontline immunotherapy combinations, biomarker and companion diagnostics, AI-enabled pathology, minimally invasive screening, precision therapies for uterine sarcomas, and tele-oncology expansion in un…
(RTTNews) - Context Therapeutics Inc. (CNTX) reported financial results for the second quarter ended June 30, 2026, reflecting a wider year-over-year loss as it prepares to progress its clinical pipeline. The company also highlighted vario…
(RTTNews) - Context Therapeutics Inc. (CNTX), a clinical-stage biopharmaceutical company, on Monday announced the addition of the company to the small-cap Russell 2000 and Russell 3000 indices as on June 26, 2026. The Russell 3000 index li…
Context Therapeutics Inc. (NASDAQ:CNTX) ranks among the overlooked penny stocks to buy right now, supported by strong upside potential. A sharp stock selloff tied to early clinical data has drawn a series of analysts defending the shares a…
[Panorama cityscape view of Aerial View of Downtown Manhattan at Sunrise, New York City, USA.] JK1991/iStock via Getty Images Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out.…
[US Food and Drug Administration (FDA)] Context Therapeutics (CNTX [https://seekingalpha.com/symbol/CNTX]) added ~11% on Thursday after the cancer drug developer said that the U.S. Food and Drug Administration (FDA) issued its Fast Track D…
(RTTNews) - Context Therapeutics Inc. (CNTX) on Thursday said the U.S. Food and Drug Administration has granted Fast Track Designation to its drug candidate CTIM-76 for the treatment of platinum-resistant ovarian cancer in patients who hav…
(RTTNews) - Context Therapeutics Inc. (CNTX), a clinical-stage biopharmaceutical company, reported its full-year 2025 financial results, reflecting a wider net loss, and outlined upcoming milestones across its investigational pipeline targ…
VANCOUVER, British Columbia, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Equity-Insider.comNews Commentary – The FDA is moving to require just one clinical trial for new drug approvals, signaling a dramatic shift toward faster regulatory pathways th…
PHILADELPHIA, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, tod…
* Context Therapeutics press release [https://seekingalpha.com/pr/20295545-context-therapeutics-reports-third-quarter-2025-operating-and-financial-results] (CNTX [https://seekingalpha.com/symbol/CNTX]): Q3 GAAP EPS of -$0.10 misses by $0.0…
Ongoing Phase 1 trial of CTIM-76 (CLDN6 x CD3) demonstrates encouraging antitumor activity and safety Ongoing Phase 1 trial of CT-95 (MSLN x CD3) is approaching target dose levels Cash and cash equivalents of $76.9 million as of September…
Step Pharma Karen Smith, MD, PhD, MBA, LLM, joins with over 25 years of global pharma and biotech experience, having contributed to more than 20 regulatory approvals Dr Smith's appointment will accelerate Step Pharma's ‘pipeline in a produ…
Karen Smith, MD, PhD, MBA, LLM, joins with over 25 years of global pharma and biotech experience, having contributed to more than 20 regulatory approvals Dr Smith's appointment will accelerate Step Pharma's ‘pipeline in a product’ strategy…
PHILADELPHIA, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today annou…
PHILADELPHIA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, tod…
PHILADELPHIA, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today annou…
PHILADELPHIA, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today annou…
CONTEXT THERAPEUTICS INC. (NASDAQ:CNTX [https://www.chartmill.com/stock/quote/CNTX]) REPORTS Q2 2025 RESULTS: WIDER LOSS THAN EXPECTED, PIPELINE PROGRESS CONTINUES Context Therapeutics Inc. posted a net loss of $8.8 million, or $0.09 per s…
CTIM-76 and CT-95 Phase 1 dose-escalation studies ongoing Cash and cash equivalents of $83.5 million as of June 30, 2025 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, Aug. 06, 2025 (…
Dosing cohort 3 of Phase 1 trial of CTIM-76, a Claudin 6 x CD3 T cell engager Expect to share initial data in the first half of 2026 PHILADELPHIA, June 02, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq…
PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced…
PHILADELPHIA, May 12, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announ…
CTIM-76 and CT-95 in Phase 1 Clinical Trials Cash and cash equivalents of $89.4 million as of March 31, 2025 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, May 07, 2025 (GLOBE NEWSWIR…
PHILADELPHIA, May 05, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced…
Preclinical data demonstrates unique binding location of CT-95 on mesothelin and avoidance of binding to shed mesothelin Data supports ongoing Phase 1 clinical trial for CT-95 PHILADELPHIA, April 30, 2025 (GLOBE NEWSWIRE) -- Context Therap…
CT-95 is a mesothelin x CD3 T cell engaging bispecific antibody CT-95 is Context’s second T cell engaging bispecific antibody to enter the clinic in 2025 PHILADELPHIA, April 09, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context”…
For Immediate Release Chicago, IL – April 4, 2025 – Stocks in this week’s article are Context Therapeutics Inc. CNTX, Blue Bird BLBD, Dycom Industries DY and Leidos LDOS. Bet on 4 Top-Ranked Stocks with Rising P/Es for Solid Gains Investor…
Investors often opt for the stock-picking approach that involves stocks with a low price-to-earnings (P/E) ratio. This strategy is based on the notion that the lower the P/E ratio is, the higher the stock value. The reasoning behind this i…
PHILADELPHIA, April 01, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today anno…
PHILADELPHIA, March 26, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, to…
CTIM-76 first patient dosed in January 2025 Cash and cash equivalents of $94.4 million as of December 31, 2024 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, March 20, 2025 (GLOBE NEW…
PHILADELPHIA, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced that Context has granted non-qualified…
PHILADELPHIA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced that the Company will participate in…
Hypergrowth stocks are the holy grail of traders and growth investors. These stocks can multiply a small position by two, five, 10 times, or more. In many cases, analysts like to project what stocks they believe can deliver this kind of ma…
Biotech stocks are naturally an exciting area for investment. Just one therapeutic breakthrough can change the whole trajectory of the company. Millions of dollars, partnerships with big-name pharmaceuticals, or even a buyout can follow. H…